Published in final edited form as:

Bioconj Chem. 2017 July 19; 28(7): 1916–1924. doi:10.1021/acs.bioconjchem.7b00242.

Hydrolyzable Poly(PEGA) Colistin Prodrugs through Copper-mediated Photo-induced Living Radical Polymerization

Chongyu Zhu[†], Elena K. Schneider[‡], Vasiliki Nikolaou^{†,§}, Tobias Klein[§], Jian Li^{||}, Thomas P. Davis^{§,†}, Michael R. Whittaker^{§,†}, Paul Wilson^{§,†}, Kristian Kempe^{§,†}, Tony Velkov[‡], and David M. Haddleton^{†,§,*}

[†]Department of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom

[‡]Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia

[§]ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia

^{||}Monash Biomedicine Discovery Institute, Department of Microbiology; Monash University, Clayton, Victoria 3800, Australia

Abstract

Through the recently developed copper-mediated photo-induced living radical polymerization (CP-LRP), a novel and well-defined polymeric prodrug of the antimicrobial lipopeptide colistin has been developed. A colistin initiator (Boc₅-col-Br₂) was synthesized through the modification of colistin on both of its threonine residues using a cleavable initiator linker, 2-(2-bromo-2-methylpropanoyloxy) acetic acid (BMPAA) and used for the polymerization of acrylates via CP-LRP. Polymerization proceeds from both sites of the colistin initiator, and through the polymerization of PEGA₄₈₀, three water-soluble polymer-colistin conjugates (col-PPEGA, DP = 5, 10, 20) were achieved with high yield (conv. 93%) and narrow dispersities (≤ 1.3) in 2–4 hours. Little or no effect on the structure/activity of the colistin was observed during the synthesis and most of the active colistin can be recovered from the conjugates in vitro within 2 days. Furthermore, in vitro biological analyses including disk diffusion, broth microdilution and time-kill studies suggested all the conjugates have the ability to inhibit the growth of multi-drug

*Phone: +44 2476 523256, Fax: 44 2476 528267, D.M.Haddleton@warwick.ac.uk.

[#]Present Addresses: Medherant Limited, University of Warwick Science Park, Coventry CV4 7EZ, United Kingdom

ASSOCIATED CONTENT

Supporting Information. Experimental details for the synthesis, instruments, protocols and characterizations including NMR, HPLC, and GPC data are available free of charge via the Internet at <http://pubs.acs.org>.

ORCID

Chongyu Zhu: 0000-0001-6337-178X

Elena K. Schneider: 0000-0001-6044-4824

Vasiliki Nikolaou: 0000-0002-1334-7498

Thomas P. Davis: 0000-0003-2581-4986

Michael R. Whittaker: 0000-0001-5706-3932

Paul Wilson: 0000-0002-9760-899X

Kristian Kempe: 0000-0002-0136-9403

Tony Velkov: 0000-0002-0017-7952

David M. Haddleton: 0000-0002-4965-0827

Notes

The authors declare no competing financial interests.

resistant (MDR) Gram-negative bacteria, of which col-PPEGA DP5 and DP10 showed similar or better antibacterial performance compared to the clinically relevant colistin prodrug CMS, indicating their potential as an alternative antimicrobial therapy. Moreover, considering the control over the polymerization, CP-LRP technique has the potential to provide an alternative platform for the development of polymer bioconjugates.

Graphical abstract

INTRODUCTION

The development of new antimicrobial agents against bacterial infections is difficult and time/cost consuming.¹⁻⁴ With the increasing amount of drug-resistant infections and the emergence of multi-drug resistant (MDR) Gram-negative bacteria, aka 'superbugs', a lack of effective drugs and treatments is threatening humans all over the world and might have severe consequences if no action is taken.^{5,6} Antibiotic resistance currently accounts for an estimated 50,000 deaths in the US and Europe, with estimates that the actual current death toll is ca. 700,000 worldwide. If antibiotic resistance were allowed to grow unabated the number of deaths per year would dramatically increase to an estimated 10 million by 2050.⁷ To combat these 'superbugs', colistin, an antibiotic from the polymyxin family has recently re-attracted the attention of researchers.⁸⁻¹¹ As one of the most potent peptide-based antimicrobial agents against MDR Gram-negative bacteria, colistin is a double-edged sword in clinical treatments due to its potential toxicity to human kidneys and the nervous system at high dose and sometimes required long treatment regimens.¹²⁻¹⁵ To date, several approaches have been developed for localized infection treatments, including inhaled colistin for lung infections¹⁶ or colistin patches for wound infections.¹⁷ However due to their intrinsic toxicity, intravenous applications have remained challenging.

The only FDA-approved colistin formulations available for systematic administration is the prodrug colistin methanesulfonate (CMS).¹⁸ Modified on the five colistin amines, this inactive prodrug is a less toxic compound that can be converted to active colistin *in vivo*.^{18,19} However it is widely acknowledged that the clinical application of CMS still suffers from a number of important drawbacks. For example, its pharmacokinetic properties are far from ideal due to the slow release rate, approximately 60% of the dosed CMS is excreted in the urine in the first 24 hours administration before being hydrolyzed to active colistin.²⁰ Also importantly, as there are 5 amines capable of undergoing modification during the preparation of CMS, there are potentially 32 (= 2⁵) chemical variations, including unmodified colistin, that can be present in CMS formulations, leading to both structural and

therefore dose variation from batch to batch, which can have a significant negative impact on clinical outcomes.^{19,21}

In an effort to find a replacement for CMS, a more structurally controlled polymeric colistin prodrug (col-aaPEG) has been previously developed.²² In contrast to the amine modification in CMS, an acetic acid terminal poly(ethylene glycol) methyl ether (aaPEG) was attached onto colistin threonine (Thr) residues to minimize the diversity of the modification site and to increase its bioavailability and improve its pharmacokinetics/pharmacodynamics performance. This hydrolyzable PEGylated colistin showed an encouraging *in vitro* and *in vivo* performance similar to CMS and revealed no systematic toxicity or nephrotoxicity. However, there remain two potential modification sites for the more active col-aaPEG monoconjugate and it is not easy to control selectivity between the two Thr residues. Conversely, col-aaPEG₂ with well-defined modification at both Thr residues showed a slower release rate and lower activity compared to its monoconjugate analogue. Thus, a colistin prodrug with well-defined site modification, i.e. modification at both Thr residues, with a suitable colistin release profile may be of significant advantage.

As an alternative to our previous ‘grafting-to’ strategy for colistin modification, the ‘grafting-from’ approach to protein/peptide modification confers a number of advantages. The addition of functional small molecules, unhindered by bulky polymer chains, facilitates complete and specific modification of the residues of interest on the target protein/peptide.^{23,24} Typically, using this approach moieties capable of mediating polymerization such as α -halo ester/amide initiators or thiocarbonylthio chain transfer agents are initially conjugated to proteins/peptides. The resulting modified structures can be fully and precisely characterized by conventional methods before being employed in polymerizations to afford polymer conjugates. Furthermore, the purification of the resulting conjugates is much less intensive than for ‘grafting-to’ techniques, as relatively large conjugates are easily separated from small molecule impurities, which include unreacted monomer and other necessary reagents in solution.

Recent developments in reversible-deactivation radical polymerizations (RDRP), such as reversible addition–fragmentation chain transfer polymerization (RAFT)^{25,26} and Cu-mediated polymerizations; atom transfer radical polymerization (ATRP),^{23,27} and single-electron transfer living radical polymerization (SET-LRP),^{28,29} bestow excellent control over the molecular weight and dispersity () of polymers maintaining high end-group fidelity. The use of external stimuli (i.e., pressure, electricity and light) enables polymerizations to be performed under relatively mild reaction conditions, even mimicking physiological environments, whilst maintaining and even accelerating the rate of reaction and retaining control over the polymerization.³⁰⁻³²

One such technique, Cu-mediated photo-induced polymerization (CP-LRP),^{33,34} has been studied using visible/UV light, employing a Cu^{II}(Me₆Tren)Br₂ complex in the presence of an excess of tris[2-(dimethylamino)ethyl]amine (Me₆Tren), allows polymerization to take place at and below ambient temperature with near perfect temporal control over the molecular weight, dispersity and chain-end fidelity at relatively low catalyst loadings (2 mol % w.r.t. initiator) in the absence of conventional photoinitiators or dye-sensitizers. To date

there have been no reports of this novel technique being employed for the preparation of protein/peptide-polymer conjugates via either the ‘grafting-to’ or ‘grafting-from’ methods. The versatility of the approach and its demonstrated use in the polymerization of a wide range of monomer types expands the potential polymer compositions that can be attached to peptides/proteins through the simple variation of the (co)monomer feed, which importantly includes easy access to poly[poly(ethylene glycol) methyl ether (meth)acrylate] (PPEG(M)A) grafted materials which are well established as an alternative to linear PEG.^{23, 24} Synthetic issues associated with the attachment of linear PEG to colistin are exacerbated by increasing molecular weight.³⁵ Similarly, the viscosity and crystallinity of linear PEG increases with molecular weight, as does the propensity for organ accumulation and vacuolization, making it less suitable for intravenous administration.³⁶⁻³⁸ The comb-like architecture of PPEG(M)A materials, with their PEG side chains impart a rigid rod-like structure in aqueous solution, which reduces the viscosity compared to linear PEG of the same molecular weight.³⁸ More importantly, due to its non-crystalline properties, PPEG(M)A does not demonstrate the accumulation in, or damage of, human tissues that has been attributed to linear PEG.³⁶

To address these problems, we have investigated the use of CP-LRP to prepare well-defined peptide-polymer conjugates using a ‘grafting-from’ approach for the first time. To achieve both site specificity and efficient release of colistin we have used a new hydrolytically labile α -halo ester initiating group to modify the two Thr residues. The linker has been specifically selected to provide an enhanced release rate relative to the acetic acid linker (aaPEG), which has been used previously. Conjugates have been prepared with good control of the grafted polymer molecular weight and narrow dispersities, as confirmed by full characterization of the polymers released from the conjugates. The effect of the degree of polymerization on the colistin release rate and bioactivity has been thoroughly evaluated by *in vitro* disk diffusion, broth dilution and time-kill assays. We demonstrate that, subject to efficient release, the polymeric colistin prodrugs have little or no observable effect on the structure or antimicrobial activity of the colistin.

RESULTS AND DISCUSSIONS

Design of the Initiator Linker for Colistin Conjugation

The colistin release rate from the polymeric prodrug would greatly affect the final antimicrobial activity and this phenomena would be more significant on the double modified colistin conjugate due to a two-step hydrolysis profile.²² Thus the design of the linker between colistin and the initiating group is important to the proposed ‘grafting from’ approach for the formation of a suitable prodrug candidate. In order to obtain an improved performance and a faster colistin release rate, a labile linker comparable to that present in the linear aaPEG is a required design prerequisite in order to afford a suitable hydrolysis whilst counteracting the two-step hydrolysis effect.²²

The stability of an ester is influenced by the neighboring groups of the carboxyl group. A more acidic group (quantified by the acid dissociation constant K_a) which normally has a stronger electron withdrawing effect, can act as a better leaving group, leading to a faster ester hydrolysis rate. Due to the same reason, the linear PEG-conjugate col-saPEG

hydrolyzed slower than col-aaPEG.²² Thus, based on pKa values, 2-(2-bromo-2-methylpropanoyloxy)acetic acid (BMPAA) was synthesized and chosen as the initiator linker (Scheme 1).

Prior to the attachment of this initiator linker to colistin, all colistin amine residues were protected by *tert*-butyloxycarbonyl (Boc) groups (Boc₅-col).²² The initiator linker was subsequently attached onto both colistin Thr residues using Steglich esterification (Figure 1a). As the commercial colistin contains two major components (colistin A and B), both colistin peaks with a clear molecular weight increase (414 Da) were observed from the modified product (Boc₅-col-Br₂) compared to Boc₅-col through matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-ToF MS), indicative of the attachment of two initiator groups (Figure 1b). The isotope pattern of Boc₅-col-Br₂ also suggested that this compound contains two bromine atoms (Figure 1c), further confirming the successful attachment of two initiators on Boc₅-colistin and the stability of both bromines of the initiators under the reaction conditions.

Polymerization of PEGA₄₈₀ from the Colistin Initiator

Due to both the hydrolytic and heat sensitive features of both colistin and the labile initiator linker, compatible polymerization conditions, such as low temperature and a non-aqueous solvent were required. Thus, CP-LRP was explored to achieve polymerization from the colistin initiator.³³ Although this technique has shown to be a versatile and robust platform, to the best of our knowledge, a peptide-based initiator has not yet been investigated. Moreover, it was not certain whether the UV light would have an undesirable effect on the peptide under these conditions. Firstly, methyl acrylate (MA) was used as a model monomer to study the feasibility of the polymerization (Figure 2a).

The total degree of polymerization (DP) was set to 40 (20 for each initiating site) to achieve a better resolution from both nuclear magnetic resonance (NMR) and MALDI-ToF MS analyses. The reaction was carried out under UV light ($\lambda_{\text{max}} \sim 360$ nm) with copper(II) bromide (CuBr₂) and Me₆Tren as the ligand at a ratio of 0.02:0.12:1 relative to the colistin initiator. Anhydrous DMSO was used so as to prevent initiator hydrolysis during the polymerization. A cooling plate was also applied to maintain the reaction temperature (~ 15 °C), further lowering the propensity of any side reactions. The conversion of MA was measured through NMR analysis of the reaction mixture, comparing the vinyl groups ($\delta = 5.70 - 6.35$ ppm, Figure S1b, peak b-d) against the signal of methyl group on both the unreacted monomer and the formed polymer ($\delta = 3.48 - 3.68$ ppm, Figure S1b, peak a and a'). This revealed that around 96% of the methyl acrylate was converted into polymer after 4 h polymerization. A monomodal peak with narrow dispersity (~ 1.12) was observed through gel permeation chromatography (GPC) analysis (Figure 2b, black trace), suggesting that the MA monomer polymerized successfully from the colistin initiator and that the polymerization was controlled. This also indicated that the colistin peptide structure did not disrupt the polymerization process.

As there are two initiating sites in the colistin initiator, a further cleavage experiment was performed on the PMA colistin conjugate (Boc₅-col-PMA) under basic conditions (3 wt% sodium methoxide, NaOMe) in order to investigate whether the polymerization had occurred

from both sites (Figure 2a). The cleaved product was found to be monomodal with approximately half the molecular weight of the initial polymer colistin conjugate through both GPC and MALDI-ToF MS analyses (Figure 2b-c), confirming that well-defined polymer chains were grown in a controlled way at both initiator sites in the colistin. Moreover, the peaks belonging to Boc₅-col were also observed *via* MALDI-ToF MS after the cleavage of the PMA chains (Figure 2c, red trace), indicating that the colistin structure was not affected under the polymerization conditions chosen.

Based on these positive results from the MA polymerization, PEGA₄₈₀ was polymerized at three different DPs (DP = 5, 10 and 20 per initiating site) under similar conditions (Figure 3). As expected, most of the PEGA₄₈₀ was consumed after 2-4 h (monomer conversion 93%, Table 1) and all the final products retained narrow dispersities (~ 1.1 -1.2, Figure 3b-d and Table 1), suggesting the successful synthesis of all the polymers in a controlled manner.

Subsequently, the polymers were treated with trifluoroacetic acid (TFA, 20% in dichloromethane, DCM), to remove all of the Boc groups on colistin to realise the amine residues. A clear shift to a shorter retention time was observed in all three polymers through high performance liquid chromatography (HPLC) analysis, suggesting quantitative removal of the Boc groups (Figure 3e). Further, GPC analysis revealed similar molecular weights and dispersities before and after the TFA cleavage process (Figure 3b-d), indicating the successful synthesis of colistin-PPEGA conjugates with three different DPs (col-PPEGA DP5, DP10 and DP20) with both ester bonds from the initiator linker being stable under the deprotection conditions.

Hydrolysis Test of col-PPEGA Conjugates

After obtaining the pure col-PPEGA conjugates, the hydrolysis of the linkers was investigated at both body and ambient temperature using the previously established hydrolysis method with phosphate-buffered saline (PBS, 1X, pH = 7.4) used to mimic physiological conditions (Figure 4).²² The degradation of the col-PPEGA conjugates was monitored by HPLC and revealed a two-step degradation process for all three conjugates (Figure 4b). Typically, the intensity of the col-PPEGA conjugate peak, which varied from 14 - 16 min depending on the DP of polymers, gradually reduced over time with the concomitant appearance of two peaks (9.8 - 10.6 min) of increasing intensity which are assigned to colistin A and B (Figure 4b). An intermediate peak, with a retention time approximately 1.5 min earlier than that of the conjugate peak, was attributed to the mono-cleaved col-PPEGA conjugate. These peaks appeared and continued to increase in intensity over the first 6 h after which they were observed to decrease as the result of further polymer cleavage. The cleaved PPEGA was also observed by HPLC but the signal was relatively low owing to the weak absorbance of PPEGA at 214 nm.

The released colistin peaks were then collected and subsequently analyzed by MALDI-ToF MS, which revealed that colistin was recovered unmodified and the chemical structure remained unaltered further confirming the colistin remained unchanged during both the polymerization and the TFA cleavage process (Figure S2). Moreover, it confirmed that the initiator linkers were cleaved completely from colistin and that the hydrolysis occurred at the

ester bond to the colistin rather than the ester bonds within the BMPAA linker or the PPEGA polymer.

In general, the colistin release rates and release profiles of each conjugate were similar (Figure 4c), suggesting the hydrolysis of the cleavable linker was not hindered greatly by the steric constraints imposed by the large comb-like structure of the attached polymers. However it should be noted that a slightly lower release rate (5-10%) for higher DP and hence molecular weight was observed.

Disk Diffusion Assay for In Vitro Antimicrobial Activity Evaluation of the Col-PPEGA Conjugates with Various DPs

In order to evaluate the antibiotic activity of each col-PPEGA conjugate, two MDR Gram-negative bacteria strains, *P. aeruginosa* ATCC 27853 and *A. baumannii* ATCC 19606, were first tested through disk diffusion assay. As a facile and economic standard, disk diffusion assay provide the visualization of the relative antimicrobial activity of each compound via a bacteria-free zone (zone of inhibition (ZoI)) from the bacteria-cultured agar plate. To this end, 20 µg of each conjugate were applied onto a blank disc (Ø = 0.6 cm) before being placed on a bacterium inoculated agar plate. Colistin and CMS were also tested as positive controls and saline as a negative control. The potency of each conjugate could be estimated through the measurement of the diameter of ZoI (Table 2).

As PEG itself has been shown to exhibit no antibiotic activity and the molecular weight of each col-PPEGA conjugate (Table S1) is at least 5-10 times larger than colistin and CMS, it was expected that they would demonstrate a lower activity with the same mass. We found that indeed col-PPEGA DP20 did not show a significant activity during the test, however, the other two col-PPEGA conjugates still showed a clear ZoI, indicating the potency of the released colistin from these colistin conjugates. Although the ZoIs are smaller than the ones obtained from colistin and CMS, the observed antimicrobial activity obtained from col-PPEGA DP5 and DP10 suggested the cleavable linker can be effectively hydrolyzed under these model physiological conditions, and importantly that this 'grafting-from' approach for colistin conjugation did not alter the biological activity of the released colistin.

Quantitative In Vitro Antimicrobial Activity Evaluation of the Col-PPEGA Conjugates with Various DPs via Broth Microdilution Method

A further examination for the minimum inhibitory concentration (MIC) of each conjugate was performed through a broth microdilution method to achieve a more accurate quantitative comparison. Although all the obtained polymer colistin conjugates have a narrow dispersity, an accurate comparison through the molar basis is not possible. Thus, the MIC test was conducted on a mass basis.

All of the col-PPEGA conjugates have shown antibacterial activity against *Ab* ATCC 19606, indicating active colistin can be released from these colistin conjugates (Table 3). Particularly, all these conjugates have comparable or better antimicrobial activity than the previous reported doubly functionalized col-aaPEG₂ even though the molecular weight of these conjugates are all larger than col-aaPEG₂. This suggests that the PPEGA polymer with the BMPAA linker released colistin faster than aaPEG₂ and that the molecular weight of the

comb-like PPEGA did not greatly hinder the linker hydrolysis which is in agreement with the colistin release profile from previous studies. Furthermore, col-PPEGA DP5 has a similar activity to the commercial prodrug CMS although the average molecular weight is around five times larger, highlighting its potential as a more efficacious alternative to CMS.

Kinetics of In Vitro Antimicrobial Activity of the Col-PPEGA Conjugates with Various DPs

To study the effects of the colistin release rate and the DP of the polymer employed in the col-PPEGA conjugates upon their antibacterial kinetics, time-kill studies of the conjugates were performed against the *A. baumannii* ATCC 19606 at three different doses referenced to their MICs ($0.5 \times \text{MIC}$, $1 \times \text{MIC}$, and $4 \times \text{MIC}$, referring to mass based MICs of each compound). Note, if a range of MICs was obtained e.g. col-PPEGA DP10 (Table 3), calculations were based on the higher MIC value.

All conjugates showed no significant inhibition towards the bacteria at the lower doses of $0.5 \times \text{MIC}$ or $1 \times \text{MIC}$. When applying a higher dose ($4 \times \text{MIC}$), both the DP5 (Figure 5a) and DP10 (Figure 5b) polymer-colistin conjugates were found to have a similar antibacterial performance when compared to the commercial prodrug CMS (Figure S4b), causing a significant decrease of the amount of live bacteria in the broth. Notably, it took 3h for DP5 conjugates ($\text{MIC } 4\times$) to inhibit the growth of bacteria to levels approaching the detection limit, while around 6h was needed for either DP10 conjugate or CMS, suggesting the colistin release rate from the conjugates played an important role for their bacteria inhibition profiles. Although the DP20 polymer conjugate (Figure 5c) did not produce a similar effect found from the DP5 and DP10 conjugates, an inhibition of bacteria growth was still observed through the experiment, suggesting antibacterial activity caused by the successful release of colistin.

CONCLUSION

In conclusion, we have demonstrated a novel and facile approach for the synthesis of colistin polymeric prodrugs with enhanced properties. A range of hydrolyzable polymer colistin conjugates have been successfully synthesized using a colistin initiator, which has been site selectively modified with two cleavable initiator precursors (BMPAA) at both Thr residues, and a novel ‘grafting-from’ approach *via* CP-LRP. Through a model PMA system, it was confirmed that initiator sites resulted in similar chain growth in a controlled manner and the structural integrity of colistin during the polymerization process. Site specific colistin-PPEGA conjugates (col-PPEGA) with different DPs have been successfully synthesized with narrow dispersities ($\sim 1.1\text{--}1.2$) using PEGA₄₈₀ monomer and fully characterized. Moreover, degradation studies under simulated physiological conditions suggested that most of the native colistin can be recovered from all three conjugates within 48 hours. The colistin release rate from the three PPEGA conjugates were similar though it slightly decreased with increasing DP of the attached polymers. *In vitro* antimicrobial activity tests revealed that all three conjugates remained active against the tested MDR Gram-negative bacteria. In particular, col-PPEGA DP5 and DP10 showed similar or better antibacterial activities to CMS. In summary, the combination of state-of-the-art CP-LRP and traceless polymer-peptide conjugation methods enabled the synthesis of well-defined col-

PPEGA systems and highlighted their potential as prodrug alternatives to CMS. Moreover, it was demonstrated that this CP-LRP methodology represents a powerful approach for the 'grafting-from' polymer modification of biological entities and opens new opportunities for future polymer-peptide conjugation strategies.

EXPERIMENTAL PROCEDURES

Synthesis of initiator precursor, 2-((2-bromo-2-methylpropanoyl)oxy)acetic acid (BMPAA)

Glycolic acid (3.00 g, 40 mmol, 1.0 equiv.) was dissolved with DCM (60 mL) and *N,N*-diisopropylethylamine (DIPEA, 8 mL, 45 mmol, 1.125 equiv.) in a 250 mL 3-neck round bottom flask under N₂. The reaction mixture was kept stirring in an ice bath for 30 min before the dropwise addition of α -bromoisobutyryl bromide (6 mL, 50 mmol, 1.25 equiv.) along with DCM (30 mL) through a dropping funnel. After the addition of all the chemicals, the system was gradually warmed up to room temperature and left overnight. The solvent was subsequently removed under vacuum and the crude product was extracted by diethyl ether/0.2 M hydrochloric acid (HCl) solution to remove the remaining DIPEA. After the removal of solvent, the product was then purified by Kugelrohr Distillation. The product is normally obtained as a white solid with a slight amount of an acid impurity (which we suspected it to be α -bromoisobutyric acid) at 50 °C to 100 °C under 2.2×10^{-2} mbar. The purity of the product can be analyzed by TLC plate (diethyl ether: AcOH = 400: 1 v/v). A further purification can be performed by the recrystallization from hot hexane. The final product consists of white flaky crystals with a yield of 3.6 g (16 mmol, 40%). ¹H-NMR (300 MHz, CDCl₃, 298 K) δ (ppm) = 1.99 (-C(CH₃)₂Br), 4.76 (-OCH₂CO-) and 7.83 (br, -COOH). ¹³C-NMR (75.5 MHz, CDCl₃, 298 K) δ (ppm) = 30.73 (-C(CH₃)₂Br), 54.56 (-C(CH₃)₂Br), 61.12 (-OCH₂CO-), 171.21 (-COOCH₂CO-), 172.74 (-OCH₂CO-). IR (neat) ν /cm⁻¹: 3300-2300 (O-H), 2975, 2865 (CH₂, CH₃), 1724, 1706 (C=O), 1421, 1248, 1147. HR-MS (ESI, negative mode): *m/z* (found) 222.9607 (M-H), *m/z* (calculated) 222.9611 (M-H).

Synthesis of Boc₅-colistin-Br₂ (Boc₅-col-Br₂)

The synthesis of Boc₅-colistin-Br₂ was modified from the standard Steglich esterification. 1.00 g of colistin sulphate (0.789 mmol, 1 equiv.) was converted into Boc₅-colistin based on the previous report.²² The crude Boc₅-colistin product (~ 1.10 g) was then dissolved in anhydrous THF (50 mL), following the addition of 2-((2-bromo-2-methylpropanoyl)oxy)acetic acid (885.0 mg, 3.95 mmol, 5 equiv.) and DMAP (48.0 mg, 0.393 mmol, 0.5 equiv.). After the chemicals completely dissolved, *N,N'*-dicyclohexylcarbodiimide (DCC, 977.0 mg, 4.74 mmol, 6 equiv.) was added afterwards and the reaction mixture was kept stirring overnight. The reaction mixture was then centrifuged to remove most of insoluble compounds. The solvent was then removed under vacuum and a further purification was performed by the flash column (0% -10% MeOH in DCM). The final product is a fine pale yellow powder with a total yield of 0.96 g (0.463 mmol, 59%).

Procedure for the polymerization of MA using colistin initiator Boc₅-colistin-Br₂

The polymerization condition of MA was modified from previous report.³⁹ A nail gel curing box with four 9 Watt bulbs was used as a UV source. MA was passed through a short basic

aluminium column to remove the inhibitor prior to use. A stock solution of CuBr₂ (1 mg/mL in DMSO) and the ligand Me₆TREN (6.5 μL/mL in DMSO) was freshly prepared before the reaction. MA (73 μL, 0.80 mmol, 40 equiv., 20 equiv. per arm), Boc₅-colistin-Br₂ (42 mg, 20 μmol, 1 equiv.), CuBr₂ stock solution (90 μL, 0.4 μmol, 0.02 equiv.), Me₆TREN stock solution (100 μL, 2.4 μmol, 0.12 equiv.) were added to a 2 mL vial. 102 μL DMSO was then added to make the monomer/solvent ratio to around 1: 4. The reaction mixture was then stirred until all the compounds were dissolved. The system was then sealed and carefully degassed by purging with N₂ for 15 min (make sure the monomer is not blown off by the N₂). The polymerization was performed under UV with a cooling plate (CAMLAB, KP283) to maintain the reaction temperature. The reaction was stopped at 4h and the conversion were measured using ¹H-NMR (Figure S1). MALDI-ToF MS and GPC analyses were also conducted to evaluate the molecular weight and dispersity of the polymer (Figure 2).

The cleavage of the linker from PMA-Boc₅-colistin conjugate was conducted directly using the crude polymer obtained from previous procedure. 100 μL of the crude polymer was diluted by 1 mL 3% NaOMe in MeOH and the reaction mixture was kept stirring at ambient temperature for 1 day. The solvent was then blown off by N₂ and the product were analysis by MALDI-ToF MS and GPC (Figure 2).

Polymerization of PEGA₄₈₀ of different DPs using colistin initiator Boc₅-colistin-Br₂

The polymerization procedure of PEGA₄₈₀ was similar to that used for MA. The ratio of [initiator]: [CuBr₂]: [ligand] was kept the same as the one used in the polymerization of MA (1: 0.02: 0.12). The PEGA₄₈₀ monomer to initiator ratio was set to 10:1, 20:1, 40:1 for the synthesis of DP5, DP10, and DP20 polymer, respectively. For the synthesis of DP10 and DP20 polymer, 21 mg colistin initiator was used and the monomer/DMSO ratio was changed to 1: 2 so that the reaction time was shorten to 2 h instead of the standard 4h to reach high monomer conversion (> 90%) which can be analyzed by ¹H-NMR. To minimise the hydrolysis during the purification steps, the further separation of the polymer and the trace PEGA₄₈₀ monomer was done by diluting the crude using ACN and purifying by RP-HPLC (0-12 min 50%-100% B; 12-20 min 100% B, 20-21 min 100%-50% B; 21-30 min 50% B). The polymer peak would be found from 8-15 min depending on the DP. Once collected from RP-HPLC, the product was frozen by liquid N₂ and the solvents were directly removed under high vacuum. The products before and after the purification were performed by GPC and HPLC analysis to observe whether any change was occurred during the purification step.

Deprotection of Boc groups from Boc₅-col-PPEGA conjugates

The cleavage of Boc groups on the colistin initiator from the polymer conjugates to regenerate col-PPEG conjugates were performed under the similar conditions described previously using 20% TFA in DCM.²² Briefly, 5 mL 20 % TFA in DCM was added slowly into the purified polymer conjugates. [Be cautious of the release of gas!] After most gas was released, the reaction mixture was sealed and kept stirring at ambient temperature overnight. After the removal of solvents, the product was frozen by liquid N₂ and all the solvents were directly removed under high vacuum. The products were performed by GPC and HPLC analysis for comparison.

Protocol for *in vitro* releasability of col-PPEGA prodrugs

The degradation of the col-PPEGA conjugates was based on the previous report.²² Each conjugate was weighed into a 2 mL vial, followed by the addition of a certain amount of PBS (1×) to make the final concentration of 0.4 μmol/mL. 900 μL of each prodrug solution was taken into another vial and incubated in an oil bath with stirring at 37 °C. The rest of each prodrug solution (> 500 μL) was stirred at room temperature. Samples (85 μL each time) were taken periodically and frozen by liquid nitrogen before the analysis. The analysis was conducted by RP-HPLC (injection volume = 70 μL) using the standard analysis condition. The colistin release percentage was calculated based on the reported method.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

C. Z. was funded by an EPSRC DTA award (1367109). P. W. acknowledges the Leverhulme Trust for an Early Career Fellowship (ECF/2015-075). K.K. thanks the award of an NHMRC-ARC Dementia Research Development Fellowship (APP1109945). The authors gratefully acknowledge the financial support from the Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (project number CE140100036). J.L. and T.V. are supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (R01 AI111965). J. L. is an Australian National Health and Medical Research Council (NHMRC) Senior Research Fellow, and T. V. is an Australian NHMRC Industry Career Development Level 2 Research Fellow. E.K.S. is an appointed Young Ambassador for the American Society of Microbiology (ASM US) and acknowledges support from the Australian Postgraduate Award.

Abbreviations

CP-LRP	copper-mediated photo-induced living radical polymerization
colistin initiator	Boc ₅ -col-Br ₂
BMPAA	2-(2-bromo-2-methylpropanoyloxy) acetic acid
PPEGA	poly[poly(ethylene glycol) methyl ether acrylate]
CMS	colistin methanesulfonate
MA	methyl acrylate
DP	degree of polymerization
	dispersities
ZoI	zone of inhibition
MIC	minimum inhibitory concentration
PBS	phosphate-buffered saline
DMSO	dimethyl sulfoxide
DCM	dichloromethane

References

1. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. *Perspect Medicin Chem.* 2014; 6:25–64. [PubMed: 25232278]
2. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. *Clin Infect Dis.* 2004; 38:1279–1286. [PubMed: 15127341]
3. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. *Nat Rev Drug Discov.* 2002; 1:895–910. [PubMed: 12415249]
4. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. *Lancet Infect Dis.* 2005; 5:115–119. [PubMed: 15680781]
5. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P&T.* 2015; 40:277–283. [PubMed: 25859123]
6. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. *Crit Care Med.* 2001; 29:N75–N81. [PubMed: 11292879]
7. O'Neill, J. Tackling drug-resistant infections globally: final report and recommendations. 2016. http://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Accessed: 10 March, 2017
8. Roberts KD, Azad MA, Wang J, Horne AS, Thompson PE, Nation RL, Velkov T, Li J. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria. *ACS Infect Dis.* 2015; 1:568–575. [PubMed: 27525307]
9. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. *Clin Infect Dis.* 2005; 40:1333–1341. [PubMed: 15825037]
10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis.* 2006; 6:589–601. [PubMed: 16931410]
11. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. *Int J Antimicrob Agents.* 2005; 25:11–25. [PubMed: 15620821]
12. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. *Ann Intensive Care.* 2011; 1:14. [PubMed: 21906345]
13. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. *Eur J Clin Pharmacol.* 2015; 71:801–810. [PubMed: 26008213]
14. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. *Pharmacother.* 2010; 30:1279–1291.
15. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Crit Care.* 2006; 10:R27–R27. [PubMed: 16507149]
16. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram (–) nosocomial pneumonia: A case series. *Respir Med.* 2009; 103:707–713. [PubMed: 19118994]
17. Zhu C, Zhao J, Kempe K, Wilson P, Wang J, Velkov T, Li J, Davis TP, Whittaker MR, Haddleton DM. A hydrogel-based localized release of colistin for antimicrobial treatment of burn wound infection. *Macromol Biosci.* 2016; doi: 10.1002/mabi.201600320
18. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2006; 50:1953–1958. [PubMed: 16723551]
19. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. *Antimicrob Agents Chemother.* 2003; 47:1364–1370. [PubMed: 12654671]

20. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. *J Antimicrob Chemother.* 2004; 53:837–840. [PubMed: 15044428]
21. He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. *J Antimicrob Chemother.* 2013; 68:2311–2317. [PubMed: 23749953]
22. Zhu C, Schneider EK, Wang J, Kempe K, Wilson P, Velkov T, Li J, Davis TP, Whittaker MR, Haddleton DM. A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria. *J Control Release.* 2017; doi: 10.1016/j.jconrel.2017.02.005
23. Averick S, Simakova A, Park S, Konkolewicz D, Magenau AJD, Mehl RA, Matyjaszewski K. ATRP under Biologically Relevant Conditions: Grafting from a Protein. *ACS Macro Letters.* 2012; 1:6–10.
24. Cobo I, Li M, Sumerlin BS, Perrier S. Smart hybrid materials by conjugation of responsive polymers to biomacromolecules. *Nat Mater.* 2015; 14:143–159. [PubMed: 25401924]
25. Boyer C, Bulmus V, Liu J, Davis TP, Stenzel MH, Barner-Kowollik C. Well-defined protein–polymer conjugates via in situ RAFT polymerization. *J Am Chem Soc.* 2007; 129:7145–7154. [PubMed: 17500523]
26. Bulmus V. RAFT polymerization mediated bioconjugation strategies. *Polym Chem.* 2011; 2:1463–1472.
27. Siegwart DJ, Oh JK, Matyjaszewski K. ATRP in the design of functional materials for biomedical applications. *Prog Polym Sci.* 2012; 37:18–37. [PubMed: 23525884]
28. Zhang Q, Li M, Zhu C, Nurumbetov G, Li Z, Wilson P, Kempe K, Haddleton DM. Well-defined protein/peptide–polymer conjugates by aqueous Cu-LRP: synthesis and controlled self-assembly. *J Am Chem Soc.* 2015; 137:9344–9353. [PubMed: 26149497]
29. Zhang Q, Wilson P, Li Z, McHale R, Godfrey J, Anastasaki A, Waldron C, Haddleton DM. Aqueous copper-mediated living polymerization: exploiting rapid disproportionation of CuBr with Me6TREN. *J Am Chem Soc.* 2013; 135:7355–7363. [PubMed: 23597244]
30. Rzaev J, Penelle J. HP-RAFT: A free-radical polymerization technique for obtaining living polymers of ultrahigh molecular weights. *Angew Chem Int Ed.* 2004; 43:1691–1694.
31. Tanabe M, Vandermeulen GWM, Chan WY, Cyr PW, Vanderark L, Rider DA, Manners I. Photocontrolled living polymerizations. *Nat Mater.* 2006; 5:467–470. [PubMed: 16699511]
32. Magenau AJD, Strandwitz NC, Gennaro A, Matyjaszewski K. Electrochemically mediated atom transfer radical polymerization. *Science.* 2011; 332:81–84. [PubMed: 21454784]
33. Anastasaki A, Nikolaou V, Zhang Q, Burns J, Samanta SR, Waldron C, Haddleton AJ, McHale R, Fox D, Percec V, et al. Copper(II)/tertiary amine synergy in photoinduced living radical polymerization: accelerated synthesis of ω -functional and α,ω -heterofunctional poly(acrylates). *J Am Chem Soc.* 2014; 136:1141–1149. [PubMed: 24372509]
34. Jones GR, Whitfield R, Anastasaki A, Haddleton DM. Aqueous copper(II) photoinduced polymerization of acrylates: low copper concentration and the importance of sodium halide salts. *J Am Chem Soc.* 2016; 138:7346–7352. [PubMed: 27184213]
35. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. *Adv Drug Deliv Rev.* 2012; 64:116–127.
36. Ogden, J., Palmer, R. Novel polymers for enhancing therapeutic half-life and drug targeting. 2011. <http://www.ondrugdelivery.com/publications/Injectable%20Formulations%202011/WEP.pdf>. Accessed: 1 December, 2017
37. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. *Angew Chem Int Ed.* 2010; 49:6288–6308.
38. Podobnik B, Helk B, Smilovi V, Škrajnar Š, Fidler K, Jevševar S, Godwin A, Williams P. Conjugation of polyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate. *Bioconjugate Chem.* 2015; 26:452–459.
39. Anastasaki A, Nikolaou V, McCaul NW, Simula A, Godfrey J, Waldron C, Wilson P, Kempe K, Haddleton DM. Photoinduced synthesis of α,ω -telechelic sequence-controlled multiblock copolymers. *Macromolecules.* 2015; 48:1404–1411.

Figure 1.

a) The Boc-protection reaction on colistin Dab amines and the subsequent modification of the labile BMPAA initiator on colistin Thr groups, b) MALDI-ToF MS data of native colistin (black), Boc₅-col (red), and Boc₅-col-BR₂ (blue) and c) The zoom-in data of Boc₅-col-BR₂.

Figure 2.

a) Scheme of the polymerization of MA using the colistin initiator *via* CP-LRP and the further cleavage of PMA colistin conjugate using NaOMe (3% in MeOH), b) GPC and c) MALDI-ToF MS of the Boc₅-col-PMA conjugate before (black traces) and after (red traces) treating with NaOMe.

Figure 3.

a) Polymerization of PEGA₄₈₀ using CP-LRP and the cleavage of the Boc groups on the polymer, b)-d) the GPC traces of the col-PPEGA conjugates with DP = 5 (b), 10 (c), and 20 (d) in reaction mixture, after purification and after cleavage and e) the HPLC traces of the col-PPEGA conjugates before and after the Boc groups cleavage.

Figure 4.

a) Scheme of the hydrolysis process of the col-PPEGA conjugates, b) Degradation of col-PPEGA conjugates (DP = 5) at 37 °C in PBS (1X) monitoring by HPLC and c) Different colistin release profiles obtained from col-PPEGA conjugates with different DPs at 37 °C or ambient temperature.

Figure 5.
The 'time-kill' kinetics with different amount for the col-PPEGA conjugates with a) DP = 5, b) DP = 10 and c) DP = 20 (c).

Scheme 1.

Acid dissociation constant at logarithmic scale of the acids with different side groups and their relative initiator linker.

Table 1

Summary of the conversion, molecular weight and dispersities () of each conjugate analyzed from $^1\text{H-NMR}$ and GPC.

DP	Conversion (%)	M_n^{Theory} ($\text{g}\cdot\text{mol}^{-1}$)	M_n^{NMR} ($\text{g}\cdot\text{mol}^{-1}$)	M_n^{GPC} ($\text{g}\cdot\text{mol}^{-1}$)	
5	99	6875	6800	6100	1.13
10	93	11675	11000	8700	1.20
20	93	21275	19900	14400	1.21

Table 2

The diameter of zone of inhibition (ZOI) results of the colistin-PPEGA conjugates against two different Gram-negative bacteria through disk diffusion assay (24 h).

		Diameter of Zone of Inhibition (ZOI) (cm)				
	saline	colistin	CMS	col-PPEGA DP5	col-PPEGA DP10	col-PPEGA DP20
Pa ATCC 27853	0	1.8	1.7	1	0.8	0
Ab ATCC 19606	0	1.8	1.8	1.1	0.9	0.65

Table 3

The minimum inhibitory concentration (MIC) of the conjugates against two different Gram-negative bacteria on a mass basis. (Data with* was acquired from Ref. 21)

Minimum inhibitory concentration against <i>Ab ATCC 19606</i> (MIC) (mg/L)						
colistin	CMS	col-aaPEG	col-aaPEG ₂	col-PPEGA DP5	col-PPEGA DP10	col-PPEGA DP20
1*	16*	8*	32*	16	16-32	16-32